$471 Bn GLP-1 Analogues Markets: Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity - Global Forecast to 2032 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.

The GLP-1 Analogues market is expected to reach USD 471.1 billion by 2032 from USD 47.4 billion in 2024, at a CAGR of 33.2%

The key factors driving the growth of the GLP-1 Analogues market include the growing popularity of the GLP-1 drug class for the treatment of chronic obesity and weight management and high efficacy of GLP-1 analogues for treating type 2 diabetes. Additionally, innovation focusing on the development of convenient forms of GLP-1 drugs, such as oral dosage forms and single dose autoinjectors, are expected to drive growth of GLP-1 analogues market. The GLP-1 Analogues market has been segmented based on products, format, route of administration, indication, and end-user.

By product, Zepbound (tirzepatide) drug is forecasted to grow at the fastest rate in the GLP-1 Analogues market

Based on product, the GLP-1 Analogues market is categorized into Ozempic (semaglutide), Trulicity (dulaglutide), Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (semaglutide), Saxenda (liraglutide [rDNA origin] injection), Victoza (liraglutide), Xultophy 100/3.6 (insulin degludec and liraglutide injection), Soliqua 100/33 (insulin glargine and lixisenatide injection), Zepbound (tirzepatide), Bydureon (exenatide extended-release), and other products. Zepbound is expected to experience fastest growth during the forecast period owing to factors such as approval of the drug for the treatment of obesity, exponential revenue growth observed since launch of the drug in 2023, and growing adoption of tirzepatide for obesity and weight management.

By product format, the single dose format segment accounted for the largest share in the GLP-1 Analogues market

Based on product format, the GLP-1 Analogues market is segmented into single-dose, multi-dose, and tablets. In 2023, the single-dose format segment accounted for the largest share of the GLP-1 Analogues market. Growth in this market segment can be attributed to the ease of administration and lower injection frequencies offered by single-dose format, together with the growing availability of single-dose auto-injectors.

North America: accounted for the largest share of the GLP-1 Analogues market

North America accounted for the largest share of the GLP-1 Analogues market. The large share of the North American region can be attributed to growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of GLP-1 products in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include Eli Lilly and Company (US), Novo Nordisk A/S (Denmark).

Europe: The second-largest region in the GLP-1 Analogues market

The Europe GLP-1 Analogues market is the second largest market for GLP-1 Analogue drugs. This is attributed to the presence of a large number of academic and research institutes in this region, growing investments by market players and government institutes, and an increasing focus on research and development activities.

Prominent Players

Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), AstraZeneca (UK), Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (China), Boehringer Ingelheim International GmbH (Germany), Innovent (China), Paige Biopharmaceutical (Suzhou) Co., Ltd. (China), Sciwind Biosciences Co., Ltd. (China), Zealand Pharma A/S (Denmark), Beijing Dongfang Baitai Biotechnology Co., Ltd (China), and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China).

The report provides insights on the following pointers

• Analysis of key drivers (Strong R&D pipeline, Improved relative efficacy of GLP-1 drugs), opportunities (Integration of GLP-1 drugs into telehealth and digital weight management programs), restraints (High barriers for new entrants due to duopoly), and challenges (Off-label use of GLP-1 drugs, High non-adherence to therapy after 12-24 months) influencing the growth of the GLP-1 Analogues market.
• Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the GLP-1 Analogues market.
• Market Development: Comprehensive information about lucrative markets- the report analyses the GLP-1 Analogues market across varied regions.
• Market Diversification: Exhaustive information about new drugs, untapped geographies, recent developments, and investments in the GLP-1 Analogues market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.

Key Attributes:

Report Attribute	Details
No. of Pages	316
Forecast Period	2024 - 2032
Estimated Market Value (USD) in 2024	$47.4 Billion
Forecasted Market Value (USD) by 2032	$471.1 Billion
Compound Annual Growth Rate	33.2%
Regions Covered	Global

Companies Featured

• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi
• Astrazeneca
• Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
• Boehringer Ingelheim International GmbH
• Innovent
• Paige Biopharmaceutical (Suzhou) Co. Ltd.
• Sciwind Biosciences Co. Ltd.
• Zealand Pharma A/S
• Beijing Dongfang Baitai Biotechnology Co. Ltd (Eastern Biotech)
• Sun Pharmaceutical Industries Ltd.
• Vtv Therapeutics
• Terns Pharmaceuticals, Inc.
• Altimmune
• Scohia Pharma, Inc.
• Structure Therapeutics
• Neurobo Pharmaceuticals, Inc.
• I2O Therapeutics, Inc.
• Amgen Inc.
• Pfizer Inc.
• Merck & Co. Inc.
• Hanmi Pharm Co. Ltd.
• Viking Therapeutics
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/1k7q6r

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.